Lead Product(s) : MB310
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Microbiotica Reveals MOA Data for MB310 in Ulcerative Colitis Treatment
Details : MB310 is an oral live biotherapeutic product which is currently being evaluated for the treatment of patients with active, mild-to-moderate ulcerative colitis.
Product Name : MB310
Product Type : Probiotic
Upfront Cash : Inapplicable
February 21, 2025
Lead Product(s) : MB310
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDT1656
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Conduit Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Conduit, Agility Life Sciences Collaborate on Autoimmune Pipeline Formulations
Details : The partnership aims to develop new solid oral-dosage form products of its autoimmune pipeline for use in future clinical trials, which includes CDT1656 for treating autoimmune diseases.
Product Name : CDT1656
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : CDT1656
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Conduit Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : KNS366
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kynos Announces Positive Results from First-in-Human Phase I Study of KMO Inhibitor KNS366
Details : KNS366 is a first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitor, which is being evaluated for the treatment of acute and chronic inflammation.
Product Name : KNS366
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2024
Lead Product(s) : KNS366
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tibulizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Access Biotechnology
Deal Size : $112.5 million
Deal Type : Private Placement
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
Details : Net proceeds will accelerate development of ZB-106 (tibulizumab), including a planned Phase 2 trial in systemic sclerosis and another evaluating its use for hidradenitis suppurativa.
Product Name : ZB-106
Product Type : Antibody
Upfront Cash : Undisclosed
April 18, 2024
Lead Product(s) : Tibulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Access Biotechnology
Deal Size : $112.5 million
Deal Type : Private Placement
Lead Product(s) : BEN-8744
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BenevolentAI Announces Positive Topline Data From Phase Ia Study Of BEN-8744
Details : BEN-8744 is an orally administered, peripherally-restricted PDE10 inhibitor, which is being developed as a potential first-in-class treatment for patients with moderate to severe ulcerative colitis.
Product Name : BEN-8744
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : BEN-8744
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KYV-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Kyverna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Kyverna gains access to LentiVector® platform, the first commercially approved lentiviral-based gene delivery system, to use with any Kyverna product, including its anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201 which specifica...
Product Name : KYV-101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 20, 2023
Lead Product(s) : KYV-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Kyverna Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BEN-8744
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BEN-8744 is a peripherally restricted small molecule and derived from the Benevolent PlatformTM and is a potential first-in-class PDE10 inhibitor for the treatment of Ulcerative Colitis.
Product Name : BEN-8744
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : BEN-8744
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tibulizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Deep Track Capital
Deal Size : $80.0 million
Deal Type : Private Placement
Details : The funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 (tibulizumab), a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist, in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurat...
Product Name : ZB-106
Product Type : Antibody
Upfront Cash : Undisclosed
June 06, 2023
Lead Product(s) : Tibulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Deep Track Capital
Deal Size : $80.0 million
Deal Type : Private Placement
Lead Product(s) : Tibulizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Deep Track Capital
Deal Size : $80.0 million
Deal Type : Private Placement
Details : The net proceedings will be used to to initiate a Phase 2 study for ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist, in Systemic Sclerosis.
Product Name : ZB-106
Product Type : Antibody
Upfront Cash : $80.0 million
April 27, 2023
Lead Product(s) : Tibulizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Deep Track Capital
Deal Size : $80.0 million
Deal Type : Private Placement
Lead Product(s) : MB272
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Gilead Sciences
Deal Size : $405.0 million
Deal Type : Acquisition
Gilead Sciences Completes Acquisition of MiroBio
Details : The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead MB272, is a selective agonist of immune inhibitory receptor B and T-Lymphocyte Attenuator.
Product Name : MB272
Product Type : Antibody
Upfront Cash : $405.0 million
September 20, 2022
Lead Product(s) : MB272
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Gilead Sciences
Deal Size : $405.0 million
Deal Type : Acquisition